Dr. Chauhan is an expert in the treatment of bladder cancers and considered a leader in this area. Physicians can watch him as a part of this expert panel as he discusses ADSTILADRIN (nadofaragene firadenovec-vncg), the first and only FDA-approved non-replicating gene therapy for high-risk BCG-unresponsive NMIBC.

In this presentation they explore:

• The clinical efficacy and safety profile, including real-world outcomes
• See how quarterly dosing supports ease of administration
• Learn to identify patients who may benefit from therapy
• Gain confidence in reimbursement and Ferring’s support services

WATCH NOW